| 000 | 01532 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250514212516.0 | ||
| 264 | 0 | _c20050203 | |
| 008 | 200502s 0 0 eng d | ||
| 022 | _a0946-1965 | ||
| 024 | 7 |
_a10.5414/cpp42648 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHilger, R A | |
| 245 | 0 | 0 |
_aCorrelation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacology and therapeutics _cNov 2004 |
||
| 300 |
_a648-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aBenzenesulfonates _xadministration & dosage |
| 650 | 0 | 4 |
_aDiarrhea _xchemically induced |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aExanthema _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-raf _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 | _aSorafenib |
| 700 | 1 | _aKredtke, S | |
| 700 | 1 | _aScheulen, M E | |
| 700 | 1 | _aSeeber, S | |
| 700 | 1 | _aStrumberg, D | |
| 773 | 0 |
_tInternational journal of clinical pharmacology and therapeutics _gvol. 42 _gno. 11 _gp. 648-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5414/cpp42648 _zAvailable from publisher's website |
| 999 |
_c15280514 _d15280514 |
||